Effectiveness and safety of antiplatelet therapy in stroke recurrence prevention in patients with liver cirrhosis: A 2-year follow-up study

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 12, 2012, Pages 1334-1343

  Chen, Chung Yu ^a   Lee, Kun Tai ^b   Lee, Charles Tzu Chi ^a   Lai, Wen Ter ^b   Huang, Yaw Bin ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiplatelet; Clinical efficacy; Liver cirrhosis; Pharmacoepidemiology; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL READMISSION; HUMAN; HYPERLIPIDEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; STROKE;

EID: 84870655693     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3359     Document Type: Article

References (28)

1. Yazgan Y, Narin Y, Demirturk L, et al. Value of regional cerebral blood flow in the evaluation of chronic liver disease and subclinical hepatic encephalopathy. J Gastroenterol Hepatol 2003; 18: 1162-1167.
2. Iwasa M, Matsumura K, Kaito M, et al. Decrease of regional cerebral blood flow in liver cirrhosis. Eur J Gastroenterol Hepatol 2000; 12: 1001-1006.
3. Yoneda M, Fujii H, Sumida Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 1300-1306.
4. Lai CH, Cheng PY, Chen YY. Liver cirrhosis and risk of intracerebral hemorrhage: a 9-year follow-up study. Stroke 2011; 42: 2615-2617.
5. Chen YH, Chen KY, Lin HC. Non-alcoholic cirrhosis and the risk of stroke: a 5-year follow-up study. Liver Int 2011; 31: 354-360.
6. Berzigotti A, Bonfiglioli A, Muscari A, et al. Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int 2005; 25: 331-336.
7. Pradella P, Bonetto S, Turchetto S, et al. Platelet production and destruction in liver cirrhosis. J Hepatol 2011; 54: 894-900.
8. Panasiuk A, Prokopowicz D. Platelet autoantibodies in liver cirrhosis and thrombocytopenia. Rocz Akad Med Bialymst 2000; 45: 54-62.
9. Russo MW, Pierson J, Narang T, Montegudo A, Eskind L, Gulati S. Coronary artery stents and antiplatelet therapy in patients with cirrhosis. J Clin Gastroenterol 2012; 46: 339-344.
10. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-276.
11. Menguy R, Desbaillets L, Okabe S, Masters YF. Abnormal aspirin metabolism in patients with cirrhosis and its possible relationship to bleeding in cirrhotics. Ann Surg 1972; 176: 412-418.
12. Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 2000; 40: 396-401.
13. Pazhanivel M, Jayanthi V. Diabetes mellitus and cirrhosis liver. Minerva Gastroenterol Dietol 2010; 56: 7-11.
14. Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol 2008; 49: 595-599.
15. Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1year after stroke. Neurology 2011; 77: 1182-1190.
16. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153-1158.
17. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236-242.
18. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690. DOI: 10.1136/bmj.d2690.:d2690.
19. Castro-Fernandez M, Sanchez-Munoz D, Galan-Jurado MV, et al. Influence of nonsteroidal antiinflammatory drugs in gastrointestinal bleeding due to gastroduodenal ulcers or erosions in patients with liver cirrhosis. Gastroenterol Hepatol 2006; 29: 11-14.
20. Sarkiss MG, Yusuf SW, Warneke CL, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007; 109: 621-627.
21. Fujita K, Nozaki Y, Wada K, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008; 57: 1583-1591.
22. Assy N, Hussein O, Khalil A, et al. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci 2007; 52: 1187-1193.
23. Hillbom M, Numminen H, Juvela S. Recent heavy drinking of alcohol and embolic stroke. Stroke 1999; 30: 2307-2312.
24. Lowyck I, Fevery J. Statins in hepatobiliary diseases: effects, indications and risks. Acta Gastroenterol Belg 2007; 70: 381-388.
25. Cadranel JF, Seddik M, Loric S, Jeanne S. Statins: hepatotoxicity and monitoring. Presse Med 2009; 38: 717-725.
26. Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly 2008; 138: 415-419.
27. Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209: 178-183.
28. Abu RM, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010; 55: 2086-2088.